Friday, July 12, 2024 3:53:54 PM
Dr. Kendall, Ph.D, is Chief Science Officer of Catena Bio, a company whose technology enables them to synthesize novel biomolecules in any structure, combination, or orientation. Previously, Dr. Kendall was the President and CEO of ImmPACT BIO, a cell therapy company developing engineered T cells for the treatment of cancer. Notably, Dr. Kendall also held significant positions at leading biopharmaceutical companies, serving as Vice President of Research at Kite Pharma, where he was responsible for the company’s research pipeline and development of CAR-T technologies, as well as Executive Director and Head of Oncology Research at Amgen.
https://drug-dev.com/pluri-launches-novel-immunotherapy-platform-for-solid-tumor-treatment/
Recent PLUR News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 11:30:34 AM
- Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates • GlobeNewswire Inc. • 07/18/2024 06:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 11:30:21 AM
- Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply • GlobeNewswire Inc. • 07/08/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 11:00:32 AM
- Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges • GlobeNewswire Inc. • 06/18/2024 10:30:00 AM
- U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract • GlobeNewswire Inc. • 06/06/2024 10:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:05:18 PM
- Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale • GlobeNewswire Inc. • 05/20/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/09/2024 08:13:36 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/09/2024 08:10:54 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:00:37 PM
- Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method • GlobeNewswire Inc. • 04/08/2024 11:00:00 AM
- Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences • GlobeNewswire Inc. • 03/28/2024 11:15:00 AM
- Pluri Inc. Announces 1-for-8 Reverse Share Split • GlobeNewswire Inc. • 03/27/2024 11:00:00 AM
- Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report • GlobeNewswire Inc. • 03/21/2024 11:00:00 AM
- Engage with Pluri's Talent: Exciting Conference Appearances Ahead • GlobeNewswire Inc. • 03/19/2024 08:00:00 AM
- Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing • GlobeNewswire Inc. • 03/14/2024 11:00:00 AM
- Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals • GlobeNewswire Inc. • 02/28/2024 12:00:00 PM
- Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 10:43:05 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:34:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2024 09:01:45 PM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM